ライフサイエンスコーパス: research and development

1 nMw (the Netherlands Organisation for Health Research and Development).

2 ions, thereby providing a roadmap for future research and development.

3 tic to the requirements of biopharmaceutical research and development.

4 -life is a key parameter for optimization in research and development.

5 r should have wide application in biological research and development.

6 US Veterans Health Administration Office of Research and Development.

7 ty a convenient way to use these methods for research and development.

8 onsensus, and highlight areas needing future research and development.

9 ful knowledge that can reliably guide future research and development.

10 ic materials that are currently under active research and development.

11 ng agenda setting for ecological forecasting research and development.

12 ViiV Healthcare and Janssen Research and Development.

13 gs as well as for applications in antibiotic research and development.

14 ng a critical material challenge for applied research and development.

15 ses clinical trial data for accelerating ALS research and development.

16 nstitutions designed to facilitate nanoscale research and development.

17 t Change Fund, NHS Greater Glasgow and Clyde Research and Development.

18 l Group for Hematology Oncology, and Janssen Research and Development.

19 us potential biomarkers in varying stages of research and development.

20 Netherlands Organisation for Health Research and Development.

21 US$ are spent globally on infectious disease research and development.

22 nal returns of investments in pharmaceutical research and development.

23 data in real time remains an area for future research and development.

24 ntives that will stimulate new antibacterial research and development.

25 als focusing on change to health systems and research and development.

26 cant opportunities to improve pharmaceutical research and development.

27 emanding a strategic rethink of conventional research and development.

28 K, PD, and PK/PD in antibiotic and antiviral research and development.

29 very diverse applications of microbiological research and development.

30 fore, insights are offered to encourage more research and development.

31 l circuits and discuss directions for future research and development.

32 ed data and bioinformatics tools for vaccine research and development.

33 s limitations, and point to areas for future research and development.

34 this field and offers directions for further research and development.

35 s have also occurred recently in stent graft research and development.

36 ysts and presenting opportunities for future research and development.

37 nd an enormous current challenge in terms of research and development.

38 here is little systematic tracking of global research and development.

39 acyclics LLC, an AbbVie Company, and Janssen Research and Development.

40 represent an active field in pharmaceutical research and development.

41 Bayer AG, Janssen Research and Development.

42 entified major cost drivers to guide further research and development.

43 and a massive current challenge in terms of research and development.

44 g valuable information for biopharmaceutical research and development.

45 ties are reviewed with a focus on the latest research and developments.

46 t trend away from natural product discovery, research, and development.

47 In traditional vaccine research and development, a single high-dose virus chall

48 Research and development activities directed toward comm

49 d annotations to this resource to accelerate research and development activities globally.

50 y, opportunities and strategies for on-going research and development activities in titanium catalysi

51 identified and discussed, as well as current research and development activities of academic, commerc

52 After two decades of research and development activity focussed on orally act

53 The result is a research and development agenda to accelerate malaria el

54 was also supported in part by a Cooperative Research and Development Agreement between NIH and Gilea

55 Program; supported in part by a cooperative research and development agreement between the National

56 to examine ways to incentivise antibacterial research and development and ensure a healthy pipeline o

57 ew, we outline the current state of adjuvant research and development and how formulation parameters

58 ies, and professionals working in antibiotic research and development and medical ethics.

59 The Netherlands Organisation for Health Research and Development and the Canadian Institutes of

60 Managing this complexity requires ingenuity, research and development, and dedicated resources.

61 needed to increase funding for tuberculosis research and development, and governments in high-burden

62 The Netherlands Organisation for Health Research and Development, and the NutsOhra Fund.

63 of Research and Development, Health Services Research and Development, and VA Information Resource Ce

64 A RAND-like (Research and Development) appropriateness methodology wa

65 The perspectives for future research and development are also described.

66 limitations of DTI and key areas for future research and development are also discussed.

67 acceptable for RGS, particularly if further research and development are done to improve the perform

68 ion are discussed, and directions for future research and development are identified.

69 8360.FUNDINGMayo Clinic, Biomedical Advanced Research and Development Authority (75A50120C00096), Nat

70 Biomedical Advanced Research and Development Authority (BARDA), PATH, bioCSL

71 Biomedical Advanced Research and Development Authority in the US Department

72 o the cutting edge of thin-film photovoltaic research and development because of their promise for hi

73 c, synthetic, and translational microbiology research and development beyond a few model organisms.

74 listed as priority concerns in a recent WHO research and development blueprint initiative for emergi

75 overnment policies; industry's role in using research and development capabilities to promote healthi

76 l product development and supply, increasing research and development capacity, and addressing gaps i

77 The Ohio State University-Ohio Agricultural Research and Development Center (OSU-OARDC), is a public

78 Houston Veterans Affairs Health Services Research and Development Center of Excellence and the Na

79 nanowires and graphene, and outline the main research and development challenges in the field.

80 1 day (range, 0-74 days), and review by the research and development committee took a median of 15 d

81 he Iowa City Veterans Affairs Medical Center Research and Development Committee.

82 tudy was approved by the Regional Ethics and Research and Development Committees.

83 Research and development connect technology and innovati

84 Using a modified Research AND Development Corporation (RAND)/University o

85 ere is no evidence of an association between research and development costs and prices; rather, presc

86 ken, thus potentially significantly reducing research and development costs and time.

87 This study provides an estimate of research and development costs for new therapeutic agent

88 objective insights and analytics to support research and development decision making and planning.

89 only epidemiology but also social sciences, research and development, diplomacy, logistics and crisi

90 the new redox mediators and points to a new research and development direction for DSCs.

91 ction of methanol and DME and outline future research and development directions.

92 c Health England and UK Department of Health Research and Development Directorate.

93 lide perovskites transformed optoelectronics research and development during the past decade.

94 Research and development efforts for biofuel production

95 International research and development efforts in Africa have brought

96 ion on therapeutic efficacy, where increased research and development efforts may lead to next-genera

97 Recently, research and development efforts on room-temperature sod

98 This manuscript details the process research and development efforts that enabled the synthe

99 f pertinent knowledge expands through future research and development efforts.

100 ersector and interdisciplinary collaborative research and development efforts.

101 Research and development enabling new technological appr

102 n of a sustainable global antibacterial drug research and development enterprise with the power in th

103 (FDA) between 2009 and 2018 to estimate the research and development expenditure required to bring a

104 Research and development expenditures were available for

105 law in economics, ranging from large firms, research and development expenditures, gross domestic pr

106 nd when considering only companies reporting research and development expense (gross profit margin: d

107 nced when considering company size, year, or research and development expense.

108 ch laboratories and diagnostic companies for research and development, facilitating collaboration bet

109 Following nearly 40 years of research and development, FDS instruments are now starti

110 spite increased investment in pharmaceutical research and development, fewer and fewer new drugs are

111 capital investments in much more profitable research and development fields.

112 ts included 128 stakeholders engaged in food research and development, food manufacturing and retail,

113 brief account of the status of therapeutics research and development for dengue.

114 global functions, such as support for health research and development for diseases of poverty and str

115 In 2012, US$1.3 billion was spent on research and development for new vaccines for neglected

116 isk of SAEs, justifying continued efforts in research and development for safer drugs and control str

117 hrough pending regulatory reforms, increased research and development for the monitoring, control, an

118 Region of Scania Research and Development Foundation and Hassleholm Hospi

119 ations could produce a framework to move the research and development from concept to reality.

120 United States-Israel Binational Agricultural Research and Development Fund (BARD) and organized in Ei

121 occur if service firms were to reach median research and development funding.

122 However, their research and development has been slowed by several fact

123 CAR T-cell therapy research and development has built on experience generat

124 arge variability and a lack of resources for research and development have resulted in highly uncerta

125 s, Veterans Health Administration, Office of Research and Development, Health Services Research and D

126 rs, Veterans Health Administration Office of Research and Development, Health Services Research and D

127 old design are reviewed and areas for future research and development highlighted.

128 Examples of research and development in a still embryonic field are

129 The approach to research and development in biomedical science is changi

130 t hold great promises for the advancement of research and development in complex biomedical systems,

131 atively basic in interventional oncology, as research and development in medical imaging focuses on i

132 ng barocaloric materials to the forefront of research and development in order to achieve safe enviro

133 f graphene materials have stimulated intense research and development in the field of bioelectrochemi

134 This review highlights research and development in the field of emerging viral

135 Finally, an overview of the ongoing research and development in the field of interventional

136 on for quantum-scale inputs is key to future research and development in these cognate areas.

137 Research and development in these two important areas ar

138 disease, yet after nearly a half-century of research and development in this field we remain without

139 Reorienting research and development in this way must overcome three

140 It is difficult to determine whether research and development incentives or reducing the cost

141 a of all the rice varieties released by Rice Research and Development Institute, Sri Lanka, and the r

142 ment of a global, publicly funded antibiotic research and development institute.

143 in the pharmaceutical landscape, tremendous research and development interest exists in developing l

144 d genetic surveillance will assist and boost research and development into new antiviral drugs and va

145 lishments, traditional Chinese medicine, and research and development investment in drug discovery.

146 sts of failed trials, the median capitalized research and development investment to bring a new drug

147 nnovators deciding during trading that their research and development investments should be reduced,

148 alth effects (both intended and unintended), research and development investments, quality and taste

149 ed to consider availability, health effects, research and development investments, reformulated food

150 ic agents have been few, and the funding for research and development is almost non-existent.

151 tic methods within the discipline of Process Research and Development is presented.

152 Considerable research and development is underway to produce fuels fr

153 A significant amount of battery research and development is underway, both in academia a

154 ne-vinyl acetate (EVA) copolymers in initial research and development led to commercial drug delivery

155 Beside devices developed at research and development level a brief revision of comme

156 ($3.27 billion) of funding was allocated to research and development (mainly for vaccines and microb

157 ing new vaccines to market, such as funding, research and development, manufacturing, determination o

158 ray Inc, Netherlands Organisation for Health Research and Development, NCI Cancer Center Support, NCI

159 urvivorship care plan and discusses areas of research and development needed to make them part of sta

160 rting a variety of complex queries driven by research and development needs.

161 National Prevention Research Initiative, NHS Research and Development; NHS National Services Scotland

162 This LCA study provides a guide to the research and development objectives that must be achieve

163 mately 20-22% are realized through intensive research and development of 1.5-1.6 eV bandgap perovskit

164 scaffolds represent promising leads for the research and development of a human respiratory syncytia

165 platform for imposing broad restrictions on research and development of all types of transgenic tree

166 ppear that from an industry perspective, the research and development of antibiotics should be an att

167 Advances in research and development of antiviral inhibitors targeti

168 l investment from government and industry in research and development of cancer preventive agents; a

169 Here, the research and development of carbon-based catalysts in su

170 parison, which is critical to facilitate the research and development of catalysts with high activity

171 National Key Projects of Research and Development of China; the Chinese Academy o

172 This article reviews the progress in the research and development of CQDs with an emphasis on the

173 Future research and development of D3R-selective antagonists an

174 Relevant animal models are important for HCV research and development of drugs and vaccines.

175 ble progress is constantly being made in the research and development of drugs for rare disorders.

176 her antibiotic-resistant bacteria to support research and development of effective drugs.

177 The major barrier to research and development of effective interventions for

178 e and our patients will benefit from further research and development of evidence-based treatments.

179 gent need for new strategies that facilitate research and development of implants with enhanced osseo

180 tical studies bring the new insights for the research and development of intercalation compounds as e

181 An urgent need for greater investment in research and development of long-acting drugs with dual

182 undoubtedly become a new paradigm for future research and development of metal additive manufacturing

183 This achievement is a turning point in the research and development of Mg electrolytes that has dee

184 idelines are presented to facilitate further research and development of more optimized CEP systems.

185 s review collocates current knowledge in the research and development of nanocelluloses and emphasize

186 This work can significantly benefit the research and development of nanoscale STT-MRAM.

187 enge, this article discusses advances in the research and development of neutralizing antibodies (nAb

188 Organization as a critical priority for the research and development of new antimicrobial therapies.

189 ds have been increasingly used to accelerate research and development of new biomaterials.

190 Beyond continued research and development of new drugs, a focus on drug r

191 The most recent progress in the research and development of new materials as well as the

192 0 years, the recent enhanced activity in the research and development of new TB drugs is extremely en

193 s to improving this situation is driving the research and development of new technologies for toilets

194 t effect of GERD on quality of life, further research and development of new therapies are needed for

195 Additionally, accelerated research and development of new tools that can be deploy

196 sive summary of the preclinical and clinical research and development of nintedanib from the initial

197 nt VVC and highlight the need for additional research and development of novel therapeutics targeting

198 ew article takes a retrospective look at the research and development of OPV, and focuses on recent a

199 Their tremendous success has spurred research and development of other metal-based drugs, wit

200 ble therapy optimization and invigorates the research and development of QSIs for clinical use.

201 tically encoded sensors can act as tools for research and development of smart plant sensors.

202 and provides a unique small-animal model for research and development of therapeutic interventions.

203 regulatory issues that deter progress of AR research and development of therapeutics targeting AR an

204 ion and suggest promising avenues for future research and development of therapies.

205 Over the past 15 years, research and development of these materials have become

206 With further research and development of this exciting class of drugs

207 So far, research and development of tuberculosis vaccines has re

208 Substantial progress has been made in research and development of tuberculosis vaccines in the

209 IRD facilitates the research and development of vaccines, diagnostics and th

210 s around nanovoids is a fundamental task for research and development of various materials.

211 An important aspect in the research and development of white light-emitting diodes

212 Finally, some perspectives on the future research and development of YSNs are provided.

213 surveillance, community-based participatory research, and development of a diverse clinical and publ

214 stimulating further investment in education, research, and development of these dedicated small-anima

215 on for non-polluting vehicles, and extensive research and development on all aspects of this technolo

216 Despite more than two decades of research and development on nucleic acid vaccines, there

217 In this review, the authors summarize the research and development on stimuli-controllable diffrac

218 To date, research and development on such a framework have proven

219 ll succeed in revolutionising pharmaceutical research and development only if these interactions are

220 ing a route towards streamlined micro-device research and development onto clinical use.

221 rrent energy landscape and discusses several research and development opportunities and pathways that

222 oscopy may find applications in agrochemical research and development or in studies of wax deposition

223 lucidate primary cost drivers and prioritize research and development pathways toward commercial feas

224 s of medical instruments, many remain in the research and development phase despite persistent effort

225 We analysed the research and development pipeline of drugs and vaccines

226 st-effectiveness analysis can help to inform research and development portfolio prioritization decisi

227 Biosensor technology is an active field of research and development presenting rapid progress in re

228 wo approaches would result in very different research and development priorities.

229 pathogen in the WHO antimicrobial resistance research and development priority list.

230 nd incorporate sustainability goals into the research and development process will benefit green chem

231 China National Key Research and Development Program and Bill & Melinda Gate

232 Korean Seoul City Research and the National Research and Development Program for Cancer Control, Min

233 k was funded by grants from the National Key Research and Development Program of China (Grant No.

234 National Key Research and Development Program of China, National Natu

235 ter for Human Brain Protection, National Key Research and Development Program of China, National Scie

236 Emergency Project of COVID-19, National Key Research and Development Program of China, the Beijing S

237 The National Key Research and Development Program of China.

238 81672367, 81572329, 81572601), and the Key Research and Development Program of Jiangsu Province (No

239 National Forensic Mental Health Research and Development Programme, UK Ministry of Justi

240 Research and development programs are underway for a new

241 uel Standard and U.S. Department of Energy's research and development programs, often lack historical

242 ks of AD-continues to drive significant drug research and development programs.

243 Research and development proposals focus on sustainable

244 Health and Social Care Research and Development, Public Health Agency, Northern

245 s, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research I

246 s, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research I

247 There are also several key research and development questions that must be addresse

248 latform MSI analysis within a pharmaceutical research and development (R&D) environment.

249 for health with additional donor spending on research and development (R&D) for diseases of poverty.

250 Research and development (R&D) for pediatric antiretrovi

251 Recommended research and development (R&D) funding was allocated to

252 t-based model of strategic link formation in Research and Development (R&D) networks.

253 n is an investment in which the costs of the Research and Development (R&D) project balance future re

254 pplying life cycle assessment (LCA) early in research and development (R&D) to guide emerging technol

255 To inform research and development (R&D), we elicited 31 experts'

256 nsion of drug MoA will significantly improve research and development (R&D).

257 Postal Service in the fall of 2001, research and development related to decontamination for

258 the challenges and perspective on the future research and development relevant to MGNs as electrocata

259 esearch; Netherlands Organisation for Health Research and Development; Research Institute for Disease

260 rocess can take 10-15 years and command vast research and development resources costing over $1 billi

261 Funders need to prioritize their scarce research and development resources.

262 The Netherlands Organisation for Health Research and Development, Sanquin Blood Supply, Chest He

263 partment of Veterans Affairs Health Services Research and Development Service

264 of Research and Development, Health Services Research and Development Service, and Evidence Synthesis

265 artment of Veterans Affairs, Health Services Research and Development Service.

266 partment of Veterans Affairs Health Services Research and Development Service.

267 re discussions among scientists, physicians, research and development specialists, and public health

268 Median and mean research and development spending on new therapeutic age

269 puts have failed to keep pace with increased research and development spending.

270 These trade-offs reveal that clonal research and development, strategic corporate and govern

271 esource, we propose a two-pronged antibiotic research and development strategy based on a short-term

272 de an insightful overview of the most recent research and development successes in bioplastic materia

273 ry efficiencies approaching 20 per cent, the research and development targets for CdTe are to reduce

274 Overall, we identify four avenues of research and development that can serve the dual purpose

275 This essay describes the research and development that led to the VLP vaccines; d

276 Research and development that supports new technological

277 ARC, The Netherlands Organisation for Health Research and Development, the Italian Ministry of Health

278 ain mechanisms and significant investment in research and development, the majority of analgesics ava

279 Regrouping patient care, diagnostics, research, and development, the University Hospital Insti

280 strate the potential to substantially reduce research and development time and to increase speed to m

281 significant differences in credentialing or research and development times across review types (exem

282 can support advancement on all scales, from research and development to implementation by public hea

283 Further research and development to overcome current challenges

284 ld provide greatest return on investments in research and development to remain self-sufficient.

285 cine, systems-based practice, and continuing research and development toward improving acute and chro

286 perform an analysis of global cancer surgery research and development trends over the last 10 years a

287 ng by disease, cross-cutting theme, and by a research and development value chain describing the type

288 Questionnaire -2.64 [95% CI -6.43 to 1.15]; Research and Development version 1 short-form-36 4.08 [-

289 Office of Research and Development, Veterans Health Administration

290 l efforts to stimulate commercial antibiotic research and development via public-private initiatives.

291 After more than a half century of research and development, we remain without a clinically

292 Substantial research and development will be required for E-BC comme

293 nced technical systems honed over decades of research and development, wind energy has become a mains

294 Also discussed is the status of research and development with regard to biosynthetically

295 Significant research and development would be required and a wide ra

296 Our model of internationalised public research and development would maximise scientific syner

297 Netherlands Organization for the Health Research and Development (ZonMw 92003545).

298 Netherlands Organisation for Health Research and Development (ZonMW), Region Vastra Gotaland

299 Netherlands Organization for Health Research and Development (ZonMw).

300 ard; The Netherlands Organisation for Health Research and Development (ZonMw); the Ministry of Health